Market Research Logo

Chronic Pain - Pipeline Review, H2 2016

Chronic Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Chronic Pain - Pipeline Review, H2 2016’, provides an overview of the Chronic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Chronic Pain
    • The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Chronic Pain therapeutics and enlists all their major and minor projects
    • The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Chronic Pain
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Chronic Pain
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Chronic Pain Overview
    Therapeutics Development
    Pipeline Products for Chronic Pain - Overview
    Pipeline Products for Chronic Pain - Comparative Analysis
    Chronic Pain - Therapeutics under Development by Companies
    Chronic Pain - Therapeutics under Investigation by Universities/Institutes
    Chronic Pain - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Chronic Pain - Products under Development by Companies
    Chronic Pain - Products under Investigation by Universities/Institutes
    Chronic Pain - Companies Involved in Therapeutics Development
    AbbVie Inc
    Acadia Pharmaceuticals Inc.
    Adynxx, Inc.
    Allergan Plc
    Amorsa Therapeutics Inc.
    arGEN-X BV
    Asana BioSciences, LLC
    AskAt Inc.
    Astraea Therapeutics, LLC
    Axsome Therapeutics, Inc.
    BioDelivery Sciences International, Inc.
    Biogen Inc
    Bionomics Limited
    Camurus AB
    Cara Therapeutics, Inc.
    Centrexion Therapeutics Corp
    ChironWells GmbH
    Collegium Pharmaceutical, Inc.
    Crinetics Pharmaceuticals, Inc.
    Cyclenium Pharma, Inc.
    Cytogel Pharma, LLC
    Daewoong Pharmaceutical Co., Ltd.
    Daiichi Sankyo Company, Limited
    Dompe Farmaceutici S.p.A.
    Echo Pharmaceuticals B.V.
    Egalet Corporation
    Eli Lilly and Company
    Elite Pharmaceuticals, Inc.
    Glenmark Pharmaceuticals Ltd.
    Grunenthal GmbH
    Heron Therapeutics, Inc.
    INSYS Therapeutics, Inc.
    Johnson & Johnson
    Kareus Therapeutics, SA
    KPI Therapeutics, Inc.
    Kymab Limited
    Laboratorios Del Dr. Esteve S.A.
    Lohocla Research Corporation
    Lpath, Inc.
    MD Biosciences GmbH
    Merck & Co., Inc.
    Moberg Pharma AB
    Mundipharma International Ltd
    Nanomerics Ltd
    Nektar Therapeutics
    Neura Therapeutik, LLC
    Orion Oyj
    Pacira Pharmaceuticals, Inc.
    Pain Therapeutics, Inc.
    PeriphaGen, Inc.
    Pfizer Inc.
    Phosphagenics Limited
    Prismic Pharmaceuticals, Inc.
    Purdue Pharma LP
    Relmada Therapeutics, Inc.
    Ribomic Inc.
    Sea4Us
    Shulov Innovative Science Ltd.
    Synactix Pharmaceuticals, Inc.
    Syntrix Biosystems, Inc.
    Teva Pharmaceutical Industries Ltd.
    Therapix Biosciences Ltd.
    Trevena, Inc.
    Voyager Therapeutics, Inc.
    Yooyoung Pharmaceutical Co., Ltd.
    Zynerba Pharmaceuticals, Inc.
    Chronic Pain - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (celecoxib + tramadol hydrochloride) - Drug Profile
    (hydrocodone bitartrate + palmidrol) - Drug Profile
    (morphine sulfate + palmidrol) - Drug Profile
    (naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile
    (oxycodone hydrochloride + palmidrol) - Drug Profile
    (palmidrol + pregabalin) - Drug Profile
    A-200 - Drug Profile
    AGN-XX - Drug Profile
    AGN-YY - Drug Profile
    AMS-520 - Drug Profile
    ASN-008 - Drug Profile
    AVLX-144 - Drug Profile
    AXS-06 - Drug Profile
    AYX-1 - Drug Profile
    AYX-2 - Drug Profile
    BBI-11008 - Drug Profile
    bupivacaine - Drug Profile
    bupivacaine hydrochloride - Drug Profile
    buprenorphine hydrochloride - Drug Profile
    buprenorphine hydrochloride depot - Drug Profile
    buprenorphine hydrochloride ER - Drug Profile
    buprenorphine hydrochloride long acting - Drug Profile
    cebranopadol - Drug Profile
    cetirizine hydrochloride + cromolyn sodium - Drug Profile
    cetuximab - Drug Profile
    CNTX-0290 - Drug Profile
    CNV-3000164 - Drug Profile
    CNV-3000223 - Drug Profile
    CR-4056 - Drug Profile
    CR-701 - Drug Profile
    CRB-0089 - Drug Profile
    Cyt-1010 - Drug Profile
    dexmedetomidine hydrochloride - Drug Profile
    DF-2593A - Drug Profile
    difelikefalin - Drug Profile
    dronabinol - Drug Profile
    DS-1971 - Drug Profile
    DWJ-208 - Drug Profile
    ECP-1014 - Drug Profile
    Egalet-003 - Drug Profile
    fluticasone propionate - Drug Profile
    FY-101C - Drug Profile
    FY-103B - Drug Profile
    GBR-900 - Drug Profile
    Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile
    grapiprant - Drug Profile
    HPI-201 - Drug Profile
    HS-731 - Drug Profile
    hydrocodone bitartrate ER - Drug Profile
    hydrocodone bitartrate ER - Drug Profile
    hydrocodone bitartrate ER - Drug Profile
    hydromorphone hydrochloride - Drug Profile
    Kindolor - Drug Profile
    KY-1017 - Drug Profile
    L-779976 - Drug Profile
    lacosamide - Drug Profile
    LEVI-04 - Drug Profile
    levorphanol tartrate ER - Drug Profile
    Lpathomab - Drug Profile
    MD-354 - Drug Profile
    Monoclonal Antibodies for Chronic Pain - Drug Profile
    Monoclonal Antibodies to Block Nav1.7 for Chronic Pain - Drug Profile
    morphine sulfate ER - Drug Profile
    MR-309 - Drug Profile
    NET-END - Drug Profile
    NKTR-181 - Drug Profile
    NL-001 - Drug Profile
    NL-002 - Drug Profile
    NM-0127 - Drug Profile
    Omnitram - Drug Profile
    onabotulinumtoxin A - Drug Profile
    OSX-300 - Drug Profile
    OSX-300 Backups - Drug Profile
    oxycodone hydrochloride ER - Drug Profile
    oxycodone hydrochloride ER - Drug Profile
    oxycodone hydrochloride ER - Drug Profile
    oxymorphone hydrochloride - Drug Profile
    oxymorphone hydrochloride ER - Drug Profile
    PAC-CP - Drug Profile
    palmidrol - Drug Profile
    Peptide to Block Cav2.2 for CNS Disorders - Drug Profile
    Peptides to Inhibit Ion Channel for Chronic Pain - Drug Profile
    Peptides to Target TRPV1 for Pain and Itch - Drug Profile
    PN-6047 - Drug Profile
    PRC-062 - Drug Profile
    Prostatic Acid Phosphatase - Drug Profile
    PspTx-3 - Drug Profile
    raxatrigine hydrochloride - Drug Profile
    RBM-005 - Drug Profile
    REL-1017 - Drug Profile
    SAFit2 - Drug Profile
    Small Molecule for Chronic Pain - Drug Profile
    Small Molecule for Chronic Pain - Drug Profile
    Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain - Drug Profile
    Small Molecule to Antagonize GPR-84 for Chronic Pain - Drug Profile
    Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile
    Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile
    Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile
    Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile
    Small Molecules for Chronic Wound Pain - Drug Profile
    Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile
    Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain - Drug Profile
    Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile
    Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain - Drug Profile
    Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile
    Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
    Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain - Drug Profile
    Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
    Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile
    Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile
    Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile
    Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile
    Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile
    Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile
    Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain - Drug Profile
    Small Molecules to Inhibit DAAO for Chronic Pain - Drug Profile
    Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile
    Small Molecules to Target Opioid Receptors for Chronic Pain - Drug Profile
    SYN-003 - Drug Profile
    Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile
    tanezumab - Drug Profile
    tapentadol hydrochloride IR - Drug Profile
    TRV-734 - Drug Profile
    U-2902 - Drug Profile
    UMB-425 - Drug Profile
    Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain - Drug Profile
    VM-902A - Drug Profile
    VYNAV-01 - Drug Profile
    XT-101 - Drug Profile
    YYC-301 - Drug Profile
    ZEP-3 - Drug Profile
    ZYN-001 - Drug Profile
    Chronic Pain - Dormant Projects
    Chronic Pain - Discontinued Products
    Chronic Pain - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Chronic Pain, H2 2016
    Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Development by Companies, H2 2016 (Contd..3)
    Number of Products under Development by Companies, H2 2016 (Contd..4)
    Number of Products under Development by Companies, H2 2016 (Contd..5)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Development by Companies, H2 2016 (Contd..4)
    Products under Development by Companies, H2 2016 (Contd..5)
    Products under Development by Companies, H2 2016 (Contd..6)
    Products under Development by Companies, H2 2016 (Contd..7)
    Products under Investigation by Universities/Institutes, H2 2016
    Chronic Pain - Pipeline by AbbVie Inc, H2 2016
    Chronic Pain - Pipeline by Acadia Pharmaceuticals Inc., H2 2016
    Chronic Pain - Pipeline by Adynxx, Inc., H2 2016
    Chronic Pain - Pipeline by Allergan Plc, H2 2016
    Chronic Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016
    Chronic Pain - Pipeline by arGEN-X BV, H2 2016
    Chronic Pain - Pipeline by Asana BioSciences, LLC, H2 2016
    Chronic Pain - Pipeline by AskAt Inc., H2 2016
    Chronic Pain - Pipeline by Astraea Therapeutics, LLC, H2 2016
    Chronic Pain - Pipeline by Axsome Therapeutics, Inc., H2 2016
    Chronic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2016
    Chronic Pain - Pipeline by Biogen Inc, H2 2016
    Chronic Pain - Pipeline by Bionomics Limited, H2 2016
    Chronic Pain - Pipeline by Camurus AB, H2 2016
    Chronic Pain - Pipeline by Cara Therapeutics, Inc., H2 2016
    Chronic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016
    Chronic Pain - Pipeline by ChironWells GmbH, H2 2016
    Chronic Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2016
    Chronic Pain - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
    Chronic Pain - Pipeline by Cyclenium Pharma, Inc., H2 2016
    Chronic Pain - Pipeline by Cytogel Pharma, LLC, H2 2016
    Chronic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
    Chronic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
    Chronic Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
    Chronic Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2016
    Chronic Pain - Pipeline by Egalet Corporation, H2 2016
    Chronic Pain - Pipeline by Eli Lilly and Company, H2 2016
    Chronic Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2016
    Chronic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
    Chronic Pain - Pipeline by Grunenthal GmbH, H2 2016
    Chronic Pain - Pipeline by Heron Therapeutics, Inc., H2 2016
    Chronic Pain - Pipeline by INSYS Therapeutics, Inc., H2 2016
    Chronic Pain - Pipeline by Johnson & Johnson, H2 2016
    Chronic Pain - Pipeline by Kareus Therapeutics, SA, H2 2016
    Chronic Pain - Pipeline by KPI Therapeutics, Inc., H2 2016
    Chronic Pain - Pipeline by Kymab Limited, H2 2016
    Chronic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
    Chronic Pain - Pipeline by Lohocla Research Corporation, H2 2016
    Chronic Pain - Pipeline by Lpath, Inc., H2 2016
    Chronic Pain - Pipeline by MD Biosciences GmbH, H2 2016
    Chronic Pain - Pipeline by Merck & Co., Inc., H2 2016
    Chronic Pain - Pipeline by Moberg Pharma AB, H2 2016
    Chronic Pain - Pipeline by Mundipharma International Ltd, H2 2016
    Chronic Pain - Pipeline by Nanomerics Ltd, H2 2016
    Chronic Pain - Pipeline by Nektar Therapeutics, H2 2016
    Chronic Pain - Pipeline by Neura Therapeutik, LLC, H2 2016
    Chronic Pain - Pipeline by Orion Oyj, H2 2016
    Chronic Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016
    Chronic Pain - Pipeline by Pain Therapeutics, Inc., H2 2016
    Chronic Pain - Pipeline by PeriphaGen, Inc., H2 2016
    Chronic Pain - Pipeline by Pfizer Inc., H2 2016
    Chronic Pain - Pipeline by Phosphagenics Limited, H2 2016
    Chronic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016
    Chronic Pain - Pipeline by Purdue Pharma LP, H2 2016
    Chronic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016
    Chronic Pain - Pipeline by Ribomic Inc., H2 2016
    Chronic Pain - Pipeline by Sea4Us, H2 2016
    Chronic Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016
    Chronic Pain - Pipeline by Synactix Pharmaceuticals, Inc., H2 2016
    Chronic Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016
    Chronic Pain - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
    Chronic Pain - Pipeline by Therapix Biosciences Ltd., H2 2016
    Chronic Pain - Pipeline by Trevena, Inc., H2 2016
    Chronic Pain - Pipeline by Voyager Therapeutics, Inc., H2 2016
    Chronic Pain - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016
    Chronic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Chronic Pain - Dormant Projects, H2 2016
    Chronic Pain - Dormant Projects (Contd..1), H2 2016
    Chronic Pain - Dormant Projects (Contd..2), H2 2016
    Chronic Pain - Dormant Projects (Contd..3), H2 2016
    Chronic Pain - Dormant Projects (Contd..4), H2 2016
    Chronic Pain - Dormant Projects (Contd..5), H2 2016
    Chronic Pain - Dormant Projects (Contd..6), H2 2016
    Chronic Pain - Dormant Projects (Contd..7), H2 2016
    Chronic Pain - Dormant Projects (Contd..8), H2 2016
    Chronic Pain - Discontinued Products, H2 2016
    Chronic Pain - Discontinued Products (Contd..1), H2 2016
    Chronic Pain - Discontinued Products (Contd..2), H2 2016
    List of Figures
    Number of Products under Development for Chronic Pain, H2 2016
    Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Top 10 Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report